Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 12/20 | 0.44 |
| ▸ | JAK3 | P52333 | 10/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24033 | 0.90 | EGFR (0.51) | JAK2JAK3PTK2KDRJAK1 | |
| SCHEMBL23505 | 0.89 | KMT2A (0.53) | RAD52TNK2JAK2JAK3PTK2 | |
| SCHEMBL24256 | 0.87 | EGFR (0.42) | RAD52JAK2JAK3PTK2FGFR1 | |
| SCHEMBL24074 | 0.86 | JAK2 (0.48) | JAK2JAK3PTK2KDREGFR | |
| SCHEMBL24403 | 0.85 | JAK2 (0.44) | JAK2JAK3PTK2FGFR1KDR | |
| SCHEMBL23499 | 0.81 | KCNH3 (0.55) | JAK2JAK3PTK2 | |
| SCHEMBL23403 | 0.81 | TNK2 (0.44) | RAD52TNK2JAK2JAK3PTK2 | |
| SCHEMBL23085 | 0.81 | EGFR (0.53) | TNK2JAK2JAK3PTK2JAK1 | |
| SCHEMBL25084 | 0.80 | JAK2 (0.44) | JAK2JAK3PTK2 | |
| SCHEMBL23523 | 0.78 | LMNA (0.48) | JAK2JAK3PTK2JAK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | claimed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | claimed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | RAD52 2959/4885TNK2 539/4885JAK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.